Taranabant - A story from a trial patient

A story came out back in September from a man named John who was part of the Merck Taranabant Study for the past 2 years.

Stats of the individual:
Age: Mid 50's
Beginning Weight: 250 lbs
This man claimed he lost 50 lbs in the first 10-12 months with minimal additional exercise and closely counting calories.
He then hit a wall and gained 12 pounds but then lost 7 of the twelve. During this time we wondered what happened but because Merck was tinkering with individual's amounts of the medication, he feels his dosage was significantly decreased during this time.
He mentions he had no side affects that he was aware of and other health factors have improved for him.
John also mentions that due to his experience that he sees this medication making it to the general public sometime in the future but hopes for it at a price that most can afford.

Taranabant is the generic name given to a new trial medication being tested for the fight against obesity. So far this medication looks promising.

1. Propanamide, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)-2-pyridinyl]oxy]-
2.N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide